This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Shuttle Pharmaceuticals’s 8K filing here.
Shuttle Pharmaceuticals Company Profile
Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .
Further Reading
- Five stocks we like better than Shuttle Pharmaceuticals
- Which Wall Street Analysts are the Most Accurate?
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
- Stock Dividend Cuts Happen Are You Ready?
- The Downtrend in UPS Stock Isn’t Over Yet
